FI109695B - Diagnostiska 1,4,7,10-tetraazacyklododekanbutyltrioler, deras användning som diagnostiska medel och förfarande för deras framställning - Google Patents

Diagnostiska 1,4,7,10-tetraazacyklododekanbutyltrioler, deras användning som diagnostiska medel och förfarande för deras framställning Download PDF

Info

Publication number
FI109695B
FI109695B FI911330A FI911330A FI109695B FI 109695 B FI109695 B FI 109695B FI 911330 A FI911330 A FI 911330A FI 911330 A FI911330 A FI 911330A FI 109695 B FI109695 B FI 109695B
Authority
FI
Finland
Prior art keywords
general formula
group
metal
tetraazacyclododecane
order numbers
Prior art date
Application number
FI911330A
Other languages
English (en)
Finnish (fi)
Other versions
FI911330A0 (fi
FI911330A (fi
Inventor
Heinz Gries
Hanns-Joachim Weinmann
Gabriele Schuhmann-Giampieri
Wolf-Ruediger Press
Johannes Platzek
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of FI911330A0 publication Critical patent/FI911330A0/fi
Publication of FI911330A publication Critical patent/FI911330A/fi
Application granted granted Critical
Publication of FI109695B publication Critical patent/FI109695B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (8)

1. Diagnostisk 1,4,7,10-tetraazacyklododekanbutyl-triol kännetecknad av, att den har den allmän-5 na formeln IA, r’oOC__ /---^ R2 H \ ( J 10 1 _A /\ 1 r’ooC-' \_/ -COOR vari vart och ett R1 självständigt betecknar väte eller en met-alljonekvivalent av ett element med ordningstal 21 - 29, 15 42, 44 eller 57 - 83, eller en radionuklid av ett element med ordningstal 27, 29, 31, 32, 37 - 39, 43, 49, 62, 64, 70 eller 77, och R2 betecknar en butyltriolgrupp, samt salterna av dessa föreningar med oorganiska eller or-20 ganiska baser eller aminosyror. ... 2. Förening enligt patentkrav 1, k ä n n e - .'** tecknad av att substituenterna R1 betecknar vätea- • ·’ tomer. • · · ·’ 3. Förening enligt patentkrav 1, kanne- *·’*** 25 tecknad av att minst tvä av R1-substituenterna be-tecknar en metalljonekvivalent av ett element med ordning-stal 21 - 29, 42, 44 eller 57 - 83, eller en radionuklid av ett element med ordningstal 27, 29, 31, 32, 37 - 39, 43, : 49, 62, 64, 70 eller 77. ,···. 30 4. Förening enligt patentkrav 2, känne tecknad av, att den är 10-(2,3,4-trihydroxibutyl)-\i.: 1,4,7-triskarboximetyl-l, 4,7,10-tetraazacyklododekan eller 10- (l-hydroximetyl-2,3-dihydroxipropyl)-1,4,7-triskarboxi-,:. metyl-l, 4,7,10-tetraazacyklododekan. I k » » » 35 29 109695
5. Gadoliniumkomplex kännetecknat av, att det erhällits frän 10-(2,3,4-trihydroxibutyl)-1,4,7-triskarboximetyl-1,4,7,10-tetraazacyklododekan eller 10-(1-hydroximetyl-2,3-dihydroxipropyl)-1,4,7-triskarboximetyl- 5 1,4,7,10-tetraazacyklododekan.
6. Användning av ett metallkomplex med den allmänna formeln IA väri minst tvä R1-substituenter betecknar en met-alljonekvivalent vid NMR-, röntgen-, ultraljuds- och radio-diagnostik. 10 7. Förfarande för framställning av 1,4,7,10- tetraazacyklododekanbutyltriol med den allmänna formeln IA R10OC χ^ VL* /" % 15 ^ nn n r’oOC-S\_/ \-COOR1 väri var och en R1 självständigt betecknar väte eller en metalljonekvivalent av ett element med ordningstal 21 - 29, 20 42, 44 eller 57 - 83, eller en radionuklid av ett element ... med ordningstal 27, 29, 31, 32, 37 - 39, 43, 49, 62, 64, 70 eller 77, och R2 betecknar en butyltriolgrupp, samt sal- • *’ terna av dessa föreningar med oorganiska eller organiska baser eller aminosyror, kännetecknat av att 25 ett förening med den allmänna formeln II * * · I f · K /-\ /H / N N\ (II),
30 W X \_/ x • » · '·,,,· väri X beetcknar en kväveskyddsgrupp eller grupp en grupp -CH2COOY, Y betecknar väte, en ammoniumkatjon, en alkali- > • ( ; 35 metall eller en skyddsgrupp, bringas att reagera pä i och för sig känt sätt med ett gruppen R2 i skyddad form i 30 10969b molekylen införande substrat, eventuellt avlägsnar man de i molekylen ingäende kväveskyddsgrupperna X, och de sälunda frigjorda -NH-grupperna alkyleras med ett ättiksyraderivat med den allmänna formeln III 5 HalCH2COOY (III) vari Hal betecknar klor, brom eller jod, man avlägsnar hydroxi- och eventuellt syraskyddsgrupperna 10 och den erhällna föreningen med den allmänna formeln IA, väri R1 betecknar väte, medelst en metalloxid eller ett metallsalt överföres till ett metallkomplex med den allmänna formeln IA, väri R1 betecknar en metalljonekviva-lent av ett element med ordningstal 21 - 29, 42, 44 eller 15 57 - 83, eller en radionuklid av ett element med ordningstal 27, 29, 31, 32, 37 - 39, 43, 49, 62, 64, 70 eller 77, och därefter, om sä önskas, fortfarande närvarande sura väteatomer substitueras med oorganiska och/eller organiska baser, aminosyror eller aminosyraamider. 20 « · 1 • · 1 • · I ·
FI911330A 1990-03-19 1991-03-19 Diagnostiska 1,4,7,10-tetraazacyklododekanbutyltrioler, deras användning som diagnostiska medel och förfarande för deras framställning FI109695B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4009119A DE4009119A1 (de) 1990-03-19 1990-03-19 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4009119 1990-03-19

Publications (3)

Publication Number Publication Date
FI911330A0 FI911330A0 (fi) 1991-03-19
FI911330A FI911330A (fi) 1991-09-20
FI109695B true FI109695B (sv) 2002-09-30

Family

ID=6402765

Family Applications (1)

Application Number Title Priority Date Filing Date
FI911330A FI109695B (sv) 1990-03-19 1991-03-19 Diagnostiska 1,4,7,10-tetraazacyklododekanbutyltrioler, deras användning som diagnostiska medel och förfarande för deras framställning

Country Status (17)

Country Link
US (4) US5980864A (sv)
EP (1) EP0448191B1 (sv)
JP (1) JP2968367B2 (sv)
AT (1) ATE124405T1 (sv)
AU (1) AU647091B2 (sv)
CA (1) CA2038493C (sv)
DE (3) DE4009119A1 (sv)
DK (1) DK0448191T3 (sv)
ES (1) ES2074219T3 (sv)
FI (1) FI109695B (sv)
HK (1) HK1002811A1 (sv)
HU (1) HU215964B (sv)
IE (1) IE67643B1 (sv)
IL (1) IL97592A (sv)
NO (2) NO179610C (sv)
NZ (1) NZ237461A (sv)
PT (1) PT97065B (sv)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362476A (en) * 1984-10-18 1994-11-08 Board Of Regents, The University Of Texas System Alkyl phosphonate polyazamacrocyclic cheates for MRI
US5316757A (en) * 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
DE4035760A1 (de) * 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4237943C2 (de) * 1992-11-06 1997-10-23 Schering Ag Verfahren zur Herstellung von Metallkomplexen der N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecan- und N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivate
DE4140779A1 (de) * 1991-12-06 1993-06-09 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Verfahren zur herstellung von mono-n-substituierten tetraazamakrocyclen
DE4218744C2 (de) * 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
DE4317588C2 (de) * 1993-05-24 1998-04-16 Schering Ag Fluorhaltige makrocyclische Metallkomplexe, Verfahren zu ihrer Herstellung, sowie ihre Verwendung
DE4318369C1 (de) * 1993-05-28 1995-02-09 Schering Ag Verwendung von makrocyclischen Metallkomplexen als Temperatursonden
US5874573A (en) * 1995-06-26 1999-02-23 Concat, Inc. Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy
DE19646762B4 (de) * 1996-11-04 2004-05-13 Schering Ag Verwendung von Metallverbindungen zur Herstellung von Mitteln zur Strahlentherapie von Tumoren
DE19652387A1 (de) * 1996-12-04 1998-06-10 Schering Ag Macrocyclische Metallkomplexcarbonsäuren, ihre Verwendung sowie Verfahren zu ihrer Herstellung
US20030017941A1 (en) * 1997-03-07 2003-01-23 The Procter & Gamble Company Catalysts and methods for catalytic oxidation
US20080125344A1 (en) * 2006-11-28 2008-05-29 Daryle Hadley Busch Bleach compositions
ZA981883B (en) * 1997-03-07 1998-09-01 Univ Kansas Catalysts and methods for catalytic oxidation
WO1998039406A1 (en) 1997-03-07 1998-09-11 The Procter & Gamble Company Bleach compositions
DE19724186C2 (de) * 1997-06-02 2002-07-18 Schering Ag Verfahren zur Mono- und 1,7-Bis-N-ß-Hydroxyalkylierung von Cyclen und die entsprechenden N-ß-Hydroxyalkyl-1,4,7,10-tetraazacyclododecan-Li-Salz-Komplexe
IT1297035B1 (it) * 1997-12-30 1999-08-03 Bracco Spa Derivati dell'acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
DE19816370B4 (de) * 1998-04-03 2004-09-09 Schering Ag Substituierte Mangan-D02A-Komplexe, diese enthaltende diagnostische Mittel und ihre Verwendung
EP1088559A3 (de) * 1999-09-29 2002-10-02 INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN Galenische Formulierungen
DE10064467C2 (de) * 2000-12-15 2002-10-31 Schering Ag Lithium-Komplexe von N-(1-Hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecan, deren Herstellung und Verwendung
US7011816B2 (en) * 2001-12-26 2006-03-14 Immunomedics, Inc. Labeling targeting agents with gallium-68 and gallium-67
WO2004006934A2 (de) * 2002-07-10 2004-01-22 Hans Robert Kalbitzer 1,4,7,10-tetraazacyclododecane als modulatoren des guanin-nukleotid bindenden roteins zur behandlung von tumoren
US20050192195A1 (en) * 2002-08-27 2005-09-01 Busch Daryle H. Catalysts and methods for catalytic oxidation
US20040048763A1 (en) * 2002-08-27 2004-03-11 The Procter & Gamble Co. Bleach compositions
JP2007521254A (ja) * 2003-06-25 2007-08-02 ゲルベ 診断画像用化合物
FR2867473B1 (fr) 2004-03-12 2006-06-23 Guerbet Sa Compose de porphyrines et utilisation a haut champ en irm
WO2006002875A1 (en) * 2004-07-02 2006-01-12 Bracco Imaging Spa Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain a chelating moiety with polyhydroxylated substituents
DE102009053171B4 (de) 2009-11-04 2011-07-21 Bayer Schering Pharma Aktiengesellschaft, 13353 Verfahren zur Herstellung des Calcium-Komplexes von Dihydroxy-hydroxy-methylpropyl-tetraazacyclododecan-triessigsäure (Calcobutrol)
DE102009057274B4 (de) 2009-12-02 2011-09-01 Bayer Schering Pharma Aktiengesellschaft Gadobutrolherstellung mittels Trioxobicyclo-octan
WO2011054480A1 (de) 2009-11-09 2011-05-12 Bayer Schering Pharma Aktiengesellschaft Gadobutrolherstellung mittels keramischer membran
EP2327395A1 (en) * 2009-11-23 2011-06-01 Bracco Imaging S.p.A Process for the preparation of gadobenate dimeglumine complex in a solid form
DE102010013833A1 (de) 2010-03-29 2011-09-29 Bayer Schering Pharma Aktiengesellschaft Herstellung von Gadobutrol mittels Dimethylformamiddimethylacetal
DE102010023105A1 (de) 2010-06-04 2011-12-08 Bayer Schering Pharma Aktiengesellschaft Gadobutrolherstellung im Eintopfverfahren mittels DMF-acetal und N-Methylimidazol
EP2457594A1 (en) 2010-11-05 2012-05-30 Bracco Imaging S.p.A Cest systems exhibiting a concentration independent responsiveness
KR102003570B1 (ko) 2011-04-21 2019-07-24 바이엘 인텔렉쳐 프로퍼티 게엠베하 고순도 가도부트롤의 제조
DK3753929T3 (da) 2015-12-10 2023-01-23 Bracco Imaging Spa Dimere kontrastmidler
CN108290849B (zh) 2015-12-10 2022-03-22 伯拉考成像股份公司 造影剂
WO2017178301A1 (en) 2016-04-13 2017-10-19 Bracco Imaging Spa Contrast agents
EP3519394B1 (en) 2016-09-27 2020-05-27 Bayer Pharma Aktiengesellschaft Method for producing the crystalline form of modification a of calcobutrol
WO2018069179A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
WO2018069176A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
CA3037803A1 (en) 2016-12-12 2018-06-21 Bracco Imaging Spa Dimeric contrast agents
EP3392254A1 (en) * 2017-04-20 2018-10-24 Koninklijke Philips N.V. Compounds for use in the diagnosis of a disease
KR101971435B1 (ko) 2017-08-29 2019-04-24 주식회사 엔지켐생명과학 가도부트롤 중간체 및 이를 이용한 가도부트롤의 제조 방법
US20210284662A1 (en) 2018-07-10 2021-09-16 Biophore India Pharmaceuticals Pvt. Ltd Process for the preparation of 2,2',2''-(10-((2r,3s)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid and its complexes
KR102167614B1 (ko) * 2018-08-23 2020-10-19 에스티팜 주식회사 가도부트롤의 제조방법
CN114573521B (zh) * 2020-12-01 2023-10-27 威智医药股份有限公司 一种钆布醇及其中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1491129A (en) * 1975-06-04 1977-11-09 Guerbet Sa Iodo-benzene derivatives and an x-ray contrast medium containing them
US4284620A (en) * 1979-03-23 1981-08-18 Mallinckrodt, Inc. N-(2-Hydroxyethyl)-2,4,6-triiodo-3,5-bis-(2-keto-L-gulonamido)benzamide and radiological compositions containing same
NO161560C (no) * 1980-04-17 1989-09-06 Univ California Symmetriske trijodisoftaldiamid-derivater og roentgenkontrastmidler inneholdende disse.
DE3150916A1 (de) * 1981-12-18 1983-06-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen N-hydroxyaethylierte 2,4,6-trijodaminoisiophthalsaeure-bis- trihydroxybutylamide, deren herstellung und diese enthaltende roentgenkontrastmittel"
US5059412A (en) * 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
MX174467B (es) * 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US4885363A (en) * 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
IT1224416B (it) * 1987-12-24 1990-10-04 Bracco Ind Chimica Spa Chelanti macrociclici e loro chelati
CA2102605A1 (en) * 1991-05-23 1992-11-24 Evan C. Unger Liposoluble compounds for magnetic resonance imaging
US5358704A (en) * 1993-09-30 1994-10-25 Bristol-Myers Squibb Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents

Also Published As

Publication number Publication date
IE910902A1 (en) 1991-09-25
NZ237461A (en) 1993-12-23
PT97065A (pt) 1991-10-31
HUT60478A (en) 1992-09-28
CA2038493A1 (en) 1991-09-20
HU215964B (hu) 1999-03-29
US20020176823A1 (en) 2002-11-28
DE10075007I2 (de) 2003-06-12
DE59105815D1 (de) 1995-08-03
JPH05320146A (ja) 1993-12-03
JP2968367B2 (ja) 1999-10-25
IL97592A0 (en) 1992-06-21
EP0448191A1 (de) 1991-09-25
EP0448191B1 (de) 1995-06-28
HU910874D0 (en) 1991-09-30
US6951639B2 (en) 2005-10-04
US6399043B1 (en) 2002-06-04
ATE124405T1 (de) 1995-07-15
FI911330A0 (fi) 1991-03-19
PT97065B (pt) 1998-07-31
IE67643B1 (en) 1996-04-17
NO911063D0 (no) 1991-03-18
FI911330A (fi) 1991-09-20
NO179610B (no) 1996-08-05
US5980864A (en) 1999-11-09
ES2074219T3 (es) 1995-09-01
AU647091B2 (en) 1994-03-17
DE4009119A1 (de) 1991-09-26
AU7361091A (en) 1991-09-19
CA2038493C (en) 2002-07-02
IL97592A (en) 1995-10-31
US20060078503A1 (en) 2006-04-13
DK0448191T3 (da) 1995-11-20
HK1002811A1 (en) 1998-09-18
NO2001003I1 (no) 2001-03-05
NO911063L (no) 1991-09-20
NO179610C (no) 1996-11-13

Similar Documents

Publication Publication Date Title
FI109695B (sv) Diagnostiska 1,4,7,10-tetraazacyklododekanbutyltrioler, deras användning som diagnostiska medel och förfarande för deras framställning
EP1931673B1 (en) Compounds comprising short aminoalcohol chains and metal complexes for medical imaging
RU2073005C1 (ru) Хелатное соединение металла
CN108368067B (zh) 二聚造影剂
JP4689775B2 (ja) 低毒性の常磁性金属のキレート錯体
US5417959A (en) Functionalized aza-crytand ligands for diagnostic imaging applications
FI94758B (sv) Makrocykliska föreningar, med en 3,6,9,15-tetra-azabicyklo/9.3.1/pentadekanstruktur, deras användning i NMR-, röntgen- eller radiodiagnostik användbara kompositoner, och sådana kompositioner
AU627451B2 (en) Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
SK283838B6 (sk) Komplexy kaskádových polymérov, spôsob ich výroby a farmaceutický prostriedok tieto látky obsahujúci
JPH05214096A (ja) 重合体化合物、nmr診断およびx線診断のための薬剤の製造法、この種の薬剤、製薬学的薬剤、重合体化合物の製造法および製薬学的薬剤の製造法
CN109963838B (zh) 二聚造影剂
CA2615434A1 (en) Perfluoroalkyl-containing complexes, process for their production as well as their use
EP0717737B1 (en) Chelants as contrast enhancing agents
WO2017178301A1 (en) Contrast agents
KR20050105474A (ko) 삼량체 거대고리 치환된 벤젠 유도체
AU2006272025A1 (en) Complexes containing perfluoroalkyl, method for the production and use thereof
KR101451446B1 (ko) 퍼플루오르화 peg기를 갖는 금속 킬레이트, 그의 제조 방법, 및 그의 용도
US5919431A (en) 1,4,7,10-tetraazacyclododecane derivatives, their use, pharmaceutical agents containing these compounds and process for their production

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20030006

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L207

Extension date: 20130226

PC Transfer of assignment of patent

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Free format text: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT